Liquid biopsies, tests performed on a fluid sample such as blood, are gaining traction as a viable alternative to traditional screening tests for cancer. Typical tests monitor circulating tumor cells (CTCs), cell-free DNA or cell-free RNA, or RNA from exosomes to find changes in genetic biomarkers. Such cell-free DNA or RNA tests can provide a less-expensive and less-invasive way to monitor patients throughout treatment periods, and when combined with NGS enable doctors to screen thousands of biomarkers in one sample.
NuGEN’s unique technologies enable highly efficient sample preparation of DNA or RNA from liquid biopsy samples to enable a high level of sensitivity for the detection and monitoring of genetic biomarkers.
Dr. Moshayoff and coworkers utilized the Ovation® PicoSL WTA System to characterize the profile of early stage colorectal cancer (CRC) and advanced adenomas (AA). Combining current molecular knowledge with whole transcriptome profiling of cell-free RNA, the team defines a panel of markers for both CRC and AA detection.
Dr. Pantiukh and co-workers developed a new method for non-invasive prenatal testing using a sequencing based screen of cell-free DNA samples. The method is enabled with an Ovation® Custom Target Enrichment panel. The authors propose a novel test method based on maternal/ fetal allelic differences applicable to pregnancies with fetuses of either sex.
Legendre and Gooden et. al. analyze cell free DNA in breast cancer patients and healthy individuals. Using the Ovation® Ultralow Methyl-Seq Library System, the authors define tumor-specific signatures by identifying 21 hypermethylation hotspots associated with metastatic breast cancer.